The global cancer microbiome market size was valued at USD 267.14 Million in 2024, driven by the increasing prevalence of chronic cancers across the globe. The market size is anticipated to grow at a CAGR of 19.90% during the forecast period of 2025-2034 to achieve a value of USD 1.64 billion by 2034.
The cancer microbiome offers several advantages, including the potential to gain insights into the development and spread of cancer. This understanding could help in devising strategies to prevent cancer progression or metastasis. By identifying specific microbes that either stimulate or hinder tumor growth, targeted therapies could also be developed.
The growing demand for personalized medicine worldwide is driving the global market for cancer microbiome further. The increasing number of research and development activities and increasing collaborations between the microbiome industry and academia to utilize the resources and expertise of both are likely to add significant growth to the overall global cancer microbiome market share.
In addition, increasing collaboration between key players and innovative companies to develop transformative advancements is also expected to drive the market growth. For example, The University of Texas MD Anderson Cancer Centre and Federation Bio have partnered to create a synthetic microbial consortium, which aims to expand the number of cancer patients responding to immunotherapy.
Key biotech companies are also raising funds from investors interested in the development of new cancer treatments with the help of microbiome potential. For instance, Enterome, a biotech company, aims to raise USD 108 million for its clinical studies and support clinical trials, including two Phase II studies.
Pragma Bio has also raised a whopping USD 10 million in funding. The startup aims to initiate the first part of a 10-year plan. Pragma is using artificial intelligence to create a statistical model that identifies potential candidates for microbiome investigation. The first area of focus for augmentation is immunotherapy in oncology, which has a close relationship with the microbiome. The first area of focus for augmentation is immunotherapy in oncology, which has a close relationship with microbiome.
The market development is also driven by the heavy investments by pharmaceutical companies, government agencies, and private investors, in microbiome research for cancer and the development of new therapies and products. The increased number of clinical trials to explore and create microbiome-based treatments for cancer is gaining popularity in the market, further propelling the market growth.
This product will be delivered within 3-5 business days.
Cancer Microbiome: Introduction
Microbiome refers to the population of microorganisms, including bacteria, viruses, and fungi, that exist in the human body. Cancer microbiomes, also known as tumor microbiomes, are a group of microorganisms that live in and around cancerous tumors in the human body. These microorganisms can either promote or inhibit tumor growth, depending on their effects on cancer.The cancer microbiome offers several advantages, including the potential to gain insights into the development and spread of cancer. This understanding could help in devising strategies to prevent cancer progression or metastasis. By identifying specific microbes that either stimulate or hinder tumor growth, targeted therapies could also be developed.
Global Cancer Microbiome Market Analysis
The increasing number of clinical studies to explore the potential of microbiomes in managing responses against cancer treatments are acting as a major trend for the global cancer microbiome market growth in the coming years. For example, a study was published in the Journal of Clinical Oncology studying the microbiomes with advanced biliary tract cancer to observe their response against a new treatment that combines durvalumab with cisplatin and gemcitabine.The growing demand for personalized medicine worldwide is driving the global market for cancer microbiome further. The increasing number of research and development activities and increasing collaborations between the microbiome industry and academia to utilize the resources and expertise of both are likely to add significant growth to the overall global cancer microbiome market share.
In addition, increasing collaboration between key players and innovative companies to develop transformative advancements is also expected to drive the market growth. For example, The University of Texas MD Anderson Cancer Centre and Federation Bio have partnered to create a synthetic microbial consortium, which aims to expand the number of cancer patients responding to immunotherapy.
Key biotech companies are also raising funds from investors interested in the development of new cancer treatments with the help of microbiome potential. For instance, Enterome, a biotech company, aims to raise USD 108 million for its clinical studies and support clinical trials, including two Phase II studies.
Pragma Bio has also raised a whopping USD 10 million in funding. The startup aims to initiate the first part of a 10-year plan. Pragma is using artificial intelligence to create a statistical model that identifies potential candidates for microbiome investigation. The first area of focus for augmentation is immunotherapy in oncology, which has a close relationship with the microbiome. The first area of focus for augmentation is immunotherapy in oncology, which has a close relationship with microbiome.
Global Cancer Microbiome Market Segmentations
Cancer Microbiome Market Report and Forecast 2025-2034” offers a detailed analysis of the market based on the following segments:Market Breakup by Type
- Products
- Services
Market Breakup by End User
- Hospitals
- Diagnostic Labs
Market Breakup by Region
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East and Africa
Global Cancer Microbiome Market Overview
The increasing prevalence of chronic cancers across the globe is a major factor driving the growth of the market. The increasing demand for personalized cancer treatments is also influencing the market growth. The increasing use of genome sequencing in exploring the potential of microbiome in cancer treatments, as it helps researchers to analyze the composition of microbial communities in and around cancerous tissues, is also expected to drive the market growth. The continuous advancements in research and development activities also act as a major factor driving the global cancer microbiome market growth.The market development is also driven by the heavy investments by pharmaceutical companies, government agencies, and private investors, in microbiome research for cancer and the development of new therapies and products. The increased number of clinical trials to explore and create microbiome-based treatments for cancer is gaining popularity in the market, further propelling the market growth.
Global Cancer Microbiome Market: Competitor Landscape
The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:- Novogene Corporation
- Psomagen
- PerkinElmer Genomics
- Illumina
- Thermo Fisher Scientific
- Viome
- Invivo Healthcare
- Zymo Research Corp
- Metabiomics
- CD Genomics
This product will be delivered within 3-5 business days.
Table of Contents
1 Preface
3 Cancer Microbiome Overview
4 Patient Profile
5 Cancer Microbiome Epidemiology Analysis
6 Global Cancer Microbiome Market Overview
7 Global Cancer Microbiome Market Landscape
8 Global Cancer Microbiome Market Dynamics
9 Global Cancer Microbiome Market Segmentation
10 North America Cancer Microbiome Market
11 Europe Cancer Microbiome Market
12 Asia Pacific Cancer Microbiome Market
13 Latin America Cancer Microbiome Market
14 Middle East and Africa Cancer Microbiome Market
15 Regulatory Framework
16 Patent Analysis
17 Grants Analysis
18 Clinical Trials Analysis
19 Funding and Investment Analysis
20 Partnership and Collaborations Analysis
21 Supplier Landscape
23 Company Competitiveness Analysis (Additional Insight)
24 Payment Methods (Additional Insight)
Companies Mentioned
- Novogene Corporation
- Psomagen
- PerkinElmer Genomics
- Illlumina
- Thermo Fisher Scientific
- Viome
- Invivo Healthcare
- Zymo Research Corp
- Metabiomics
- CD Genomics